As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists (GLP-1RA) market for diabetes and... BioWorld Premium Enjoy extended ...
Researchers at the University of Gothenburg found that blocking somatostatin restores glucagon release in type 1 diabetes, potentially preventing severe hypoglycemia. The study highlights the ...
Instead of inhibiting tumor cell division, as the most widely used medications do, the strategy consisted of hyperactivating oncogenic signaling by these cells to the point where they became stressed.